

CHAPTER 4

TREATMENT

Azmee Mohd Ghazi, Azhari Rosman, Rosli Mohd Ali, Robaayah Zambahari

Institut Jantung Negara

CHAPTER 4: TREATMENT

Azmee Mohd Ghazi, Azhari Rosman, Rosli Mohd Ali, Robaayah Zambahari
Institut Jantung Negara

Summary

1. Elderly patients spent more days in CCU or ICU/CICU but similar length of admission in hospital following ACS.
2. Following STEMI, 7% of patients were treated with primary angioplasty and 74% received thrombolysis.
3. Thrombolysis was given more in the young age group and primary angioplasty was provided more in the elderly age group.
4. The mean door to needle time was 105mins and the median was 50mins. The mean door to balloon time was 226mins and the median was 117mins.
5. In NSTEMI/UA, male and younger patients tend to undergo more PCI compared to female, middle age and elderly patients.
6. About 93% of patients were prescribed with aspirin and 89% of patients received statins following ACS.

In this chapter, we have summarised the treatment given to the patients admitted with acute coronary syndrome (ACS) entered in the NCVD-ACS Registry from 2006 to 2010. This chapter will also describe the pattern of admission, revascularization therapy and pharmacological therapy in patients who were admitted with ACS.

Pattern of admission

The total number of days of admission was similar in all of the ACS spectrums. The median of total number of days of admission was five days in STEMI and NSTEMI and four days in unstable angina, which was noted to be consistent between years 2006 and 2010. [Table 4.1] The total days of admission was noted to be similar in all age group (young, middle age and elderly). [Table 4.2] There was no difference in the number of days spent in hospital in all three ethnic groups (Malay, Chinese and Indian) admitted with ACS. [Table 4.4]

The number of days spent in CCU or ICU/CICU was also similar in the entire ACS spectrum. Patients admitted with STEMI, NSTEMI and unstable angina spent a median of two to three days in CCU or ICU/CICU. This was observed in each year from 2006 to 2010. [Table 4.1] The number of days spent in CCU or ICU/ICU increase with age group and this was observed in all ACS spectrums. [Table 4.2] There was no difference in the number of days spent in CCU or ICU/CICU between gender and all three ethnic groups. [Table 4.3 & Table 4.4]

Revascularisation therapy

In patients presented with STEMI, 74% received thrombolysis at presentation and 7% of patients proceeded directly to primary angioplasty. Twelve percent of patients did not receive any primary revascularization therapy (thrombolysis/primary angioplasty) because of late presentation or missed diagnosis. Four percent of patients did not receive any thrombolysis because of contraindication. [Table 4.1] Thrombolysis was given more in males (75%) than females (66%) and primary angioplasty was noted to be similar in both genders. [Table 4.3] Thrombolysis was used more in the young age group (77%) as compared to the elderly age group (69%) and vice versa noted in the group proceeded to

primary angioplasty, higher in the elderly age group (7%) and lower in the younger age group (6%). [Table 4.2] The Chinese received the least thrombolysis but the most primary angioplasty as compared to the Malays and Indians. [Table 4.4] The mean door to needle time was 105mins and median 50mins. The mean door to balloon time was 226mins and median 117mins. [Table 4.5]

In NSTEMI/UA group, most of the patients were treated medically. About 13% of patients with NSTEMI and 6% of patients with unstable angina were treated with PCI on the same admission. Two percent of patients with NSTEMI and 1% of patients with UA underwent CABG on the same admission. [Table 4.1] Male gender and younger age group tend to undergo PCI more compared to female, middle age and elderly patients. There was no difference in patients treated with PCI following NSTEMI/UA between the different ethnic groups. [Table 4.8]

Pharmacological therapy

The use of aspirin was noted to be as high as 93% and up to 72% of patients received ADP antagonist in the entire ACS spectrum. There was no difference in the use of aspirin and ADP antagonist between different age groups, gender and ethnic groups. The use of LMWH was noted to be as high as 73% and unfractionated heparin up to 11%. LMWH was given more in unstable angina and NSTEMI patients than STEMI patients. GP IIb/IIIa receptor inhibitor usage was low (<5%) in the ACS spectrum. [Table 4.1]

Up to 89% of patients admitted with ACS were treated with statins and 68% of patients were on beta-blockers. [Table 4.1] Younger patients were more likely to receive beta-blockers compared to the elderly patients. ACE inhibitors were used in up to 63% and Angiotensin II receptor blocker in up to 11%. [Table 4.1] It was noted that more males received ACE inhibitors than females following ACS [Table 4.3 & Table 4.7] but there was no difference in the use of ACE inhibitors in different age groups and race. Up to 31% of patients received oral hypoglycaemic agent and up to 27% of patients were on insulin. More Indians were on oral hypoglycaemic agent and insulin as compared to Malays and Chinese. [Table 4.4] Diuretics were used in up to 26% and anti-arrhythmic agents were used in up to 8% of patients.

Table 4.1 Summary of treatments for patients with ACS by ACS stratum, NCVD-ACS Registry, 2006-2010

| Year | ACS Stratum | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | |
|----------------------------|-------------|-------------|-------------|-------------|-------------|------------|-------------|-------------|------------|-------------|-------------|-------------|-------------|-----------|--------|----|
| | | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA |
| Total | 4647 | 2904 | 2320 | 1681 | 1046 | 867 | 1802 | 1008 | 591 | 8130 | 4958 | 4958 | 3778 | | | |
| Total admission days** | | | | | | | | | | | | | | | | |
| N | 4360 | 2763 | 2208 | 1602 | 1016 | 846 | 1536 | 892 | 543 | 7498 | 4671 | 3597 | | | | |
| Mean (SD) | 6 (3) | 6 (4) | 5 (3) | 6 (3) | 6 (4) | 5 (3) | 6 (4) | 6 (4) | 4 (2) | 6 (3) | 6 (4) | 5 (3) | | | | |
| Median (min, max) | 5 (1, 30) | 5 (1, 30) | 4 (1, 30) | 5 (1, 30) | 5 (1, 30) | 4 (1, 30) | 5 (1, 30) | 5 (1, 30) | 4 (1, 27) | 5 (1, 30) | 5 (1, 30) | 5 (1, 30) | | | | |
| IQR | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 4 | 2 | 2 | 3 | | | | |
| Number of days on CCU | | | | | | | | | | | | | | | | |
| N | 3359 | 1119 | 336 | 1220 | 488 | 373 | 1223 | 280 | 57 | 5802 | 1887 | 766 | | | | |
| Mean (SD) | 3 (3) | 3 (3) | 3 (3) | 3 (2) | 4 (4) | 3 (3) | 3 (3) | 4 (3) | 3 (1) | 3 (3) | 4 (3) | 3 (3) | | | | |
| Median (min, max) | 3 (1, 29) | 3 (1, 30) | 2 (1, 24) | 3 (1, 24) | 3 (1, 30) | 2 (1, 28) | 3 (1, 30) | 3 (1, 16) | 2 (1, 7) | 3 (1, 30) | 3 (1, 30) | 3 (1, 30) | | | | |
| IQR | 2 | 2 | 3 | 2 | 3 | 2 | 2 | 3 | 1 | 2 | 2 | 2 | | | | |
| Number of days on ICU/CICU | | | | | | | | | | | | | | | | |
| N | 108 | 155 | 40 | 36 | 22 | 6 | 23 | 12 | 7 | 167 | 189 | 53 | | | | |
| Mean (SD) | 3 (3) | 3 (3) | 3 (2) | 3 (3) | 4 (6) | 2 (1) | 3 (1) | 3 (2) | 2 (1) | 3 (3) | 4 (4) | 3 (2) | | | | |
| Median (min, max) | 2 (1, 17) | 3 (1, 24) | 3 (1, 11) | 2 (2, 14) | 3 (1, 24) | 2 (1, 4) | 3 (1, 5) | 3 (1, 8) | 2 (1, 4) | 2 (1, 17) | 3 (1, 24) | 3 (1, 11) | | | | |
| IQR | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | | | | |

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | | |
|---|-------------|-------------|-------------|-------------|-------------|------------|-------------|-------------|------------|-------------|-------------|-------------|-----------|-------|--------|----|
| | ACS Stratum | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA |
| Total | 4647 | 2904 | 2320 | 1681 | 1046 | 867 | 1802 | 1008 | 591 | 8130 | 4958 | 3778 | | | | |
| Fibrinolytic therapy, No. (%) | | | | | | | | | | | | | | | | |
| Given | 3377 (73) | | | 1258 (75) | | | | 1347 (75) | | | 5982 (74) | | | | | |
| Not given-proceeded directly to primary angioplasty | 319 (7) | | | 90 (5) | | | | 140 (8) | | | 549 (7) | | | | | |
| Not given-Contraindicated | 188 (4) | | | 82 (5) | | | | 64 (4) | | | 334 (4) | | | | | |
| Not given-Missed thrombolysis | 587 (13) | | | 201 (12) | | | | 202 (11) | | | 990 (12) | | | | | |
| Not given-Others*** | 176 (4) | | | 50 (3) | | | | 49 (3) | | | 275 (3) | | | | | |
| Cardiac catheterisation, No. (%) | | | | | | | | | | | | | | | | |
| Yes | 940 (20) | 678 (23) | 241 (10) | 425 (25) | 266 (25) | 65 (7) | 379 (21) | 181 (18) | 43 (7) | 1744 (21) | 1125 (23) | 349 (9) | | | | |
| No | 3562 (77) | 2160 (74) | 2046 (88) | 1191 (71) | 761 (73) | 789 (91) | 1334 (74) | 785 (78) | 526 (89) | 6087 (75) | 3706 (75) | 3361 (89) | | | | |
| Number transferred to another centre | 145 (3) | 66 (2) | 33 (1) | 65 (4) | 19 (2) | 13 (1) | 89 (5) | 42 (4) | 22 (4) | 299 (4) | 127 (3) | 68 (2) | | | | |
| Percutaneous Coronary Intervention, No. (%) | | | | | | | | | | | | | | | | |
| Yes | 856 (18) | 415 (14) | 167 (7) | 341 (20) | 142 (14) | 36 (4) | 275 (15) | 101 (10) | 22 (4) | 1472 (18) | 658 (13) | 225 (6) | | | | |
| No | 3791 (82) | 2489 (86) | 2153 (93) | 1340 (80) | 904 (86) | 831 (96) | 1527 (85) | 907 (90) | 569 (96) | 6658 (82) | 4300 (87) | 3553 (94) | | | | |
| CABG, No. (%) | | | | | | | | | | | | | | | | |
| Yes | 28 (1) | 83 (3) | 29 (1) | 4 (0) | 19 (2) | 9 (1) | 6 (0) | 8 (1) | 4 (1) | 38 (0) | 110 (2) | 42 (1) | | | | |
| No | 4619 (99) | 2821 (97) | 2291 (99) | 1677 (100) | 1027 (98) | 858 (99) | 1796 (100) | 1000 (99) | 587 (99) | 8092 (100) | 4848 (98) | 3736 (99) | | | | |

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | | |
|---|-------------|-------------|-------------|-------------|-------------|------------|-------------|-------------|------------|-------------|-------------|-------------|-----------|-------|--------|----|
| | ACS Stratum | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA |
| Total | 4647 | 2904 | 2320 | 1681 | 1046 | 867 | 1802 | 1008 | 591 | 8130 | 4958 | 3778 | | | | |
| Pre-admission aspirin use, No. (%) | | | | | | | | | | | | | | | | |
| Yes | 880 (19) | 1242 (43) | 1151 (50) | 383 (23) | 550 (53) | 446 (51) | 363 (20) | 426 (42) | 325 (55) | 1626 (20) | 2218 (45) | 1922 (51) | | | | |
| No | 3303 (71) | 1308 (45) | 792 (34) | 1218 (72) | 477 (46) | 400 (46) | 1350 (75) | 524 (52) | 241 (41) | 5871 (72) | 2309 (47) | 1433 (38) | | | | |
| Unknown | 464 (10) | 354 (12) | 377 (16) | 80 (5) | 19 (2) | 21 (2) | 89 (5) | 58 (6) | 25 (4) | 633 (8) | 431 (9) | 423 (11) | | | | |
| Pharmacological therapy given during admission, No. (%) | | | | | | | | | | | | | | | | |
| Aspirin | 4318 (93) | 2560 (88) | 2013 (87) | 1578 (94) | 978 (93) | 815 (94) | 1703 (95) | 935 (93) | 524 (89) | 7599 (93) | 4473 (90) | 3352 (89) | | | | |
| ADP antagonist | 3154 (68) | 1798 (62) | 1268 (55) | 1309 (78) | 850 (81) | 708 (82) | 1411 (78) | 782 (78) | 397 (67) | 5874 (72) | 3430 (69) | 2373 (63) | | | | |
| GP receptor inhibitor | 165 (4) | 99 (3) | 29 (1) | 86 (5) | 19 (2) | 6 (1) | 61 (3) | 26 (3) | 17 (3) | 312 (4) | 144 (3) | 52 (1) | | | | |
| Unfractionated heparin | 475 (10) | 377 (13) | 318 (14) | 154 (9) | 78 (7) | 38 (4) | 244 (14) | 98 (10) | 29 (5) | 873 (11) | 553 (11) | 385 (10) | | | | |
| LMWH | 1598 (34) | 2040 (70) | 1592 (69) | 714 (42) | 847 (81) | 750 (87) | 763 (42) | 737 (73) | 455 (77) | 3075 (38) | 3624 (73) | 2797 (74) | | | | |
| Beta blocker | 2957 (64) | 1864 (64) | 1598 (69) | 1012 (60) | 676 (65) | 605 (70) | 1021 (57) | 607 (60) | 376 (64) | 4990 (61) | 3147 (63) | 2579 (68) | | | | |
| ACE inhibitor | 2636 (57) | 1529 (53) | 1438 (62) | 909 (54) | 595 (57) | 596 (69) | 920 (51) | 501 (50) | 331 (56) | 4465 (55) | 2625 (53) | 2365 (63) | | | | |
| Angiotensin II receptor blocker | 221 (5) | 307 (11) | 203 (9) | 116 (7) | 131 (13) | 75 (9) | 114 (6) | 122 (12) | 69 (12) | 451 (6) | 560 (11) | 347 (9) | | | | |
| Statins | 4166 (90) | 2530 (87) | 2024 (87) | 1468 (87) | 878 (84) | 747 (86) | 1625 (90) | 881 (87) | 528 (89) | 7259 (89) | 4289 (87) | 3299 (87) | | | | |
| Other lipid lowering agent | 190 (4) | 197 (7) | 124 (5) | 142 (8) | 90 (9) | 45 (5) | 76 (4) | 57 (6) | 42 (7) | 408 (5) | 344 (7) | 211 (6) | | | | |
| Diuretics | 1187 (26) | 1137 (39) | 643 (28) | 325 (19) | 388 (37) | 188 (22) | 405 (22) | 391 (39) | 168 (28) | 1917 (24) | 1916 (39) | 999 (26) | | | | |
| Calcium antagonist | 318 (7) | 626 (22) | 489 (21) | 109 (6) | 203 (19) | 145 (17) | 94 (5) | 226 (22) | 140 (24) | 521 (6) | 1055 (21) | 774 (20) | | | | |
| Oral hypoglycaemic agent | 1053 (23) | 842 (29) | 702 (30) | 356 (21) | 303 (29) | 301 (35) | 379 (21) | 282 (28) | 182 (31) | 1788 (22) | 1427 (29) | 1185 (31) | | | | |
| Insulin | 1154 (25) | 769 (26) | 482 (21) | 349 (21) | 259 (25) | 153 (18) | 435 (24) | 286 (28) | 108 (18) | 1938 (24) | 1314 (27) | 743 (20) | | | | |
| Anti-arrhythmic agent | 359 (8) | 224 (8) | 100 (4) | 78 (5) | 91 (9) | 27 (3) | 149 (8) | 72 (7) | 24 (4) | 586 (7) | 387 (8) | 151 (4) | | | | |

Table 4.2 Treatments for patients with STEMI by age group (years), NCVD-ACS Registry, 2006-2010

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | |
|----------------------------|------------|-------------|-------------|------------|------------|------------|------------|-------------|------------|------------|-------------|-------------|-----------|-----------|
| | Age group* | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly | |
| Total | 344 | 2555 | 1748 | 145 | 909 | 627 | 146 | 1006 | 650 | 635 | 4470 | 3025 | | |
| Total admission days** | | | | | | | | | | | | | | |
| N | 324 | 2402 | 1634 | 136 | 877 | 589 | 128 | 857 | 551 | 588 | 4136 | 2774 | | |
| Mean (SD) | 5 (2) | 6 (3) | 6 (4) | 6 (2) | 6 (3) | 6 (3) | 6 (2) | 6 (3) | 6 (4) | 6 (4) | 6 (3) | 6 (4) | | |
| Median (min, max) | 5 (1, 27) | 5 (1, 30) | 5 (1, 30) | 5 (1, 18) | 5 (1, 30) | 5 (1, 30) | 5 (1, 25) | 5 (1, 16) | 5 (1, 30) | 5 (1, 28) | 5 (1, 27) | 5 (1, 30) | 5 (1, 30) | 5 (1, 30) |
| IQR | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 3 |
| Number of days on CCU | | | | | | | | | | | | | | |
| N | 244 | 1880 | 1235 | 109 | 663 | 448 | 103 | 681 | 439 | 456 | 3224 | 2122 | | |
| Mean (SD) | 3 (2) | 3 (2) | 4 (3) | 3 (2) | 4 (2) | 3 (2) | 3 (2) | 3 (2) | 3 (3) | 4 (3) | 3 (2) | 3 (2) | 3 (3) | |
| Median (min, max) | 3 (1, 17) | 3 (1, 29) | 3 (1, 28) | 3 (1, 9) | 3 (1, 21) | 3 (1, 24) | 3 (1, 12) | 3 (1, 30) | 3 (1, 20) | 3 (1, 17) | 3 (1, 30) | 3 (1, 30) | 3 (1, 28) | |
| IQR | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Number of days on ICU/CICU | | | | | | | | | | | | | | |
| N | 9 | 59 | 40 | 2 | 16 | 18 | 1 | 16 | 6 | 12 | 91 | 64 | | |
| Mean (SD) | 2 (1) | 3 (3) | 4 (4) | 3 (1) | 4 (3) | 3 (2) | 1 (.) | 3 (1) | 3 (1) | 2 (1) | 3 (3) | 4 (3) | | |
| Median (min, max) | 2 (1, 4) | 2 (1, 17) | 3 (1, 17) | 3 (2, 4) | 2 (2, 14) | 3 (2, 9) | 1 (1, 1) | 3 (1, 5) | 3 (1, 4) | 2 (1, 4) | 2 (1, 17) | 3 (1, 17) | | |
| IQR | 1 | 3 | 3 | 2 | 2 | 2 | 0 | 2 | 1 | 2 | 2 | 3 | | |

*Young is defined as age from 20 to less than 40 years, middle-age is defined as age between 40 to less than 60 years and elderly is defined as 60 years and above

**Total admission days is derived as Outcome date – Admission date + 1

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | |
|---|------------|-------------|-------------|------------|------------|------------|------------|-------------|------------|------------|-------------|-------------|-----------|--|--|
| | Age group* | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly | | |
| Total | 344 | 2555 | 1748 | 145 | 909 | 627 | 146 | 1006 | 650 | 635 | 4470 | 3025 | | | |
| Fibrinolytic therapy, No. (%) | | | | | | | | | | | | | | | |
| Given | 259 (75) | 1943 (76) | 1175 (67) | 119 (82) | 698 (77) | 441 (70) | 113 (77) | 764 (76) | 470 (72) | 491 (77) | 3405 (76) | 2086 (69) | | | |
| Not given-proceeded directly to primary angioplasty | 20 (6) | 167 (7) | 132 (8) | 6 (4) | 50 (6) | 34 (5) | 9 (6) | 90 (9) | 41 (6) | 35 (6) | 307 (7) | 207 (7) | | | |
| Not given-Contraindicated | 10 (3) | 84 (3) | 94 (5) | 3 (2) | 29 (3) | 50 (8) | 3 (2) | 23 (2) | 38 (6) | 16 (3) | 136 (3) | 182 (6) | | | |
| Not given-Missed thrombolysis | 40 (12) | 282 (11) | 265 (15) | 15 (10) | 102 (11) | 84 (13) | 19 (13) | 105 (10) | 78 (12) | 74 (12) | 489 (11) | 427 (14) | | | |
| Not given-Others*** | 15 (4) | 79 (3) | 82 (5) | 2 (1) | 30 (3) | 18 (3) | 2 (1) | 24 (2) | 23 (4) | 19 (3) | 133 (3) | 123 (4) | | | |
| Cardiac catheterisation, No. (%) | | | | | | | | | | | | | | | |
| Yes | 82 (24) | 538 (21) | 320 (18) | 44 (30) | 247 (27) | 134 (21) | 31 (21) | 221 (22) | 127 (20) | 157 (25) | 1006 (23) | 581 (19) | | | |
| No | 247 (72) | 1939 (76) | 1376 (79) | 94 (65) | 627 (69) | 470 (75) | 106 (73) | 736 (73) | 492 (76) | 447 (70) | 3302 (74) | 2338 (77) | | | |
| Number transferred to another centre | 15 (4) | 78 (3) | 52 (3) | 7 (5) | 35 (4) | 23 (4) | 9 (6) | 49 (5) | 31 (5) | 31 (5) | 162 (4) | 106 (4) | | | |
| Percutaneous Coronary Intervention, No. (%) | | | | | | | | | | | | | | | |
| Yes | 66 (19) | 501 (20) | 289 (17) | 32 (22) | 203 (22) | 106 (17) | 21 (14) | 167 (17) | 87 (13) | 119 (19) | 871 (19) | 482 (16) | | | |
| No | 278 (81) | 2054 (80) | 1459 (83) | 113 (78) | 706 (78) | 521 (83) | 125 (86) | 839 (83) | 563 (87) | 516 (81) | 3599 (81) | 2543 (84) | | | |
| CABG, No. (%) | | | | | | | | | | | | | | | |
| Yes | 0 (0) | 13 (1) | 15 (1) | 0 (0) | 3 (0) | 1 (0) | 0 (0) | 4 (0) | 2 (0) | 0 (0) | 20 (0) | 18 (1) | | | |
| No | 344 (100) | 2542 (99) | 1733 (99) | 145 (100) | 906 (100) | 626 (100) | 146 (100) | 1002 (100) | 648 (100) | 635 (100) | 4450 (100) | 3007 (99) | | | |

***'Not given-Others' includes missing and refusal

| Year | 2006-2008 | | | 2009 | | | 2010 | | | 2006-2010 | | |
|---|------------|-------------|-------------|------------|------------|------------|------------|-------------|------------|------------|-------------|-------------|
| Age group* | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly |
| Total | 344 | 2555 | 1748 | 145 | 909 | 627 | 146 | 1006 | 650 | 635 | 4470 | 3025 |
| Pre-admission aspirin use, No. (%) | | | | | | | | | | | | |
| Yes | 46 (13) | 464 (18) | 370 (21) | 25 (17) | 190 (21) | 168 (27) | 29 (20) | 196 (19) | 138 (21) | 100 (16) | 850 (19) | 676 (22) |
| No | 269 (78) | 1833 (72) | 1201 (69) | 110 (76) | 681 (75) | 427 (68) | 110 (75) | 754 (75) | 486 (75) | 489 (77) | 3268 (73) | 2114 (70) |
| Unknown | 29 (8) | 258 (10) | 177 (10) | 10 (7) | 38 (4) | 32 (5) | 7 (5) | 56 (6) | 26 (4) | 46 (7) | 352 (8) | 235 (8) |
| Pharmacological therapy given during admission, No. (%) | | | | | | | | | | | | |
| Aspirin | 322 (94) | 2391 (94) | 1605 (92) | 141 (97) | 857 (94) | 580 (93) | 141 (97) | 953 (95) | 609 (94) | 604 (95) | 4201 (94) | 2794 (92) |
| ADP antagonist | 226 (66) | 1697 (66) | 1231 (70) | 113 (78) | 719 (79) | 477 (76) | 118 (81) | 794 (79) | 499 (77) | 457 (72) | 3210 (72) | 2207 (73) |
| GP receptor inhibitor | 15 (4) | 87 (3) | 63 (4) | 6 (4) | 50 (6) | 30 (5) | 4 (3) | 36 (4) | 21 (3) | 25 (4) | 173 (4) | 114 (4) |
| Unfractionated heparin | 37 (11) | 260 (10) | 178 (10) | 13 (9) | 95 (10) | 46 (7) | 20 (14) | 151 (15) | 73 (11) | 70 (11) | 506 (11) | 297 (10) |
| LMWH | 141 (41) | 864 (34) | 593 (34) | 59 (41) | 364 (40) | 291 (46) | 66 (45) | 427 (42) | 270 (42) | 266 (42) | 1655 (37) | 1154 (38) |
| Beta blocker | 236 (69) | 1723 (67) | 998 (57) | 95 (66) | 572 (63) | 345 (55) | 89 (61) | 594 (59) | 338 (52) | 420 (66) | 2889 (65) | 1681 (56) |
| ACE inhibitor | 198 (58) | 1525 (60) | 913 (52) | 88 (61) | 466 (51) | 355 (57) | 73 (50) | 524 (52) | 323 (50) | 359 (57) | 2515 (56) | 1591 (53) |
| Angiotensin II receptor blocker | 17 (5) | 108 (4) | 96 (5) | 8 (6) | 66 (7) | 42 (7) | 14 (10) | 53 (5) | 47 (7) | 39 (6) | 227 (5) | 185 (6) |
| Statins | 306 (89) | 2316 (91) | 1544 (88) | 129 (89) | 795 (87) | 544 (87) | 129 (88) | 910 (90) | 586 (90) | 564 (89) | 4021 (90) | 2674 (88) |
| Other lipid lowering agent | 21 (6) | 115 (5) | 54 (3) | 17 (12) | 80 (9) | 45 (7) | 6 (4) | 47 (5) | 23 (4) | 44 (7) | 242 (5) | 122 (4) |
| Diuretics | 52 (15) | 576 (23) | 559 (32) | 18 (12) | 157 (17) | 150 (24) | 21 (14) | 187 (19) | 197 (30) | 91 (14) | 920 (21) | 906 (30) |
| Calcium antagonist | 14 (4) | 132 (5) | 172 (10) | 7 (5) | 58 (6) | 44 (7) | 2 (1) | 52 (5) | 40 (6) | 23 (4) | 242 (5) | 256 (8) |
| Oral hypoglycaemic agent | 60 (17) | 639 (25) | 354 (20) | 25 (17) | 200 (22) | 131 (21) | 24 (16) | 239 (24) | 116 (18) | 109 (17) | 1078 (24) | 601 (20) |
| Insulin | 55 (16) | 650 (25) | 449 (26) | 17 (12) | 186 (20) | 146 (23) | 23 (16) | 239 (24) | 173 (27) | 95 (15) | 1075 (24) | 768 (25) |
| Anti-arrhythmic agent | 17 (5) | 180 (7) | 162 (9) | 9 (6) | 31 (3) | 38 (6) | 10 (7) | 73 (7) | 66 (10) | 36 (6) | 284 (6) | 266 (9) |

Table 4.3 Treatments for patients with STEMI by gender, NCVD-ACS Registry, 2006-2010

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | |
|---|-------------|------------|-------------|------------|-------------|------------|-------------|-------------|------|--------|------|--------|-----------|--------|
| Gender | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female |
| Total | 3943 | 704 | 1452 | 229 | 1546 | 256 | 6941 | 1189 | | | | | | |
| Total admission days* | | | | | | | | | | | | | | |
| N | 3704 | 656 | 1385 | 217 | 1329 | 207 | 6418 | 1080 | | | | | | |
| Mean (SD) | 6 (3) | 7 (4) | 6 (3) | 6 (3) | 6 (4) | 7 (4) | 6 (3) | 7 (4) | | | | | | |
| Median (min, max) | 5 (1, 30) | 6 (1, 29) | 5 (1, 30) | 5 (1, 25) | 5 (1, 30) | 6 (1, 23) | 5 (1, 30) | 5 (1, 29) | | | | | | |
| IQR | 2 | 4 | 2 | 3 | 2 | 2 | 2 | 2 | | | | | | |
| Number of days on CCU | | | | | | | | | | | | | | |
| N | 2888 | 471 | 1060 | 160 | 1044 | 179 | 4992 | 810 | | | | | | |
| Mean (SD) | 3 (3) | 4 (3) | 3 (2) | 4 (3) | 3 (3) | 4 (3) | 3 (2) | 4 (3) | | | | | | |
| Median (min, max) | 3 (1, 29) | 3 (1, 28) | 3 (1, 24) | 3 (1, 24) | 3 (1, 30) | 3 (1, 19) | 3 (1, 30) | 3 (1, 28) | | | | | | |
| IQR | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | | | | | | |
| Number of days on ICU/CICU | | | | | | | | | | | | | | |
| N | 86 | 22 | 33 | 3 | 19 | 4 | 138 | 29 | | | | | | |
| Mean (SD) | 4 (3) | 3 (2) | 3 (3) | 3 (1) | 3 (1) | 3 (1) | 3 (3) | 3 (2) | | | | | | |
| Median (min, max) | 2 (1, 17) | 2 (1, 11) | 2 (2, 14) | 4 (2, 4) | 3 (1, 5) | 3 (2, 3) | 2 (1, 17) | 2 (1, 11) | | | | | | |
| IQR | 3 | 2 | 2 | 2 | 3 | 1 | 2 | 2 | | | | | | |
| Fibrinolytic therapy, No. (%) | | | | | | | | | | | | | | |
| Given | 2914 (74) | 463 (66) | 1100 (76) | 158 (69) | 1180 (76) | 167 (65) | 5194 (75) | 788 (66) | | | | | | |
| Not given-proceeded directly to primary angioplasty | 274 (7) | 45 (6) | 76 (5) | 14 (6) | 114 (7) | 26 (10) | 464 (7) | 85 (7) | | | | | | |
| Not given-Contraindicated | 150 (4) | 38 (5) | 67 (5) | 15 (7) | 45 (3) | 19 (7) | 262 (4) | 72 (6) | | | | | | |
| Not given-Missed thrombolysis | 459 (12) | 128 (18) | 165 (11) | 36 (16) | 167 (11) | 35 (14) | 791 (11) | 199 (17) | | | | | | |
| Not given-Others** | 146 (4) | 30 (4) | 44 (3) | 6 (3) | 40 (3) | 9 (4) | 230 (3) | 45 (4) | | | | | | |

**'Not given-Others' includes missing and refusal

| Year | 2006-2008 | | 2009 | | 2010 | | 2006-2010 | |
|---|------------------|---------------|-------------|---------------|-------------|---------------|------------------|---------------|
| Gender | Male | Female | Male | Female | Male | Female | Male | Female |
| Total | 3943 | 704 | 1452 | 229 | 3943 | 704 | 1452 | 229 |
| Cardiac catheterisation, No. (%) | | | | | | | | |
| Yes | 820 (21) | 120 (17) | 372 (26) | 53 (23) | 321 (21) | 58 (23) | 1513 (22) | 231 (19) |
| No | 2994 (76) | 568 (81) | 1026 (71) | 165 (72) | 1145 (74) | 189 (74) | 5165 (74) | 922 (78) |
| Number transferred to another centre | 129 (3) | 16 (2) | 54 (4) | 11 (5) | 80 (5) | 9 (4) | 263 (4) | 36 (3) |
| Percutaneous Coronary Intervention, No. (%) | | | | | | | | |
| Yes | 749 (19) | 107 (15) | 298 (21) | 43 (19) | 231 (15) | 44 (17) | 1278 (18) | 194 (16) |
| No | 3194 (81) | 597 (85) | 1154 (79) | 186 (81) | 1315 (85) | 212 (83) | 5663 (82) | 995 (84) |
| CABG, No. (%) | | | | | | | | |
| Yes | 25 (1) | 3 (0) | 4 (0) | 0 (0) | 5 (0) | 1 (0) | 34 (0) | 4 (0) |
| No | 3918 (99) | 701 (100) | 1448 (100) | 229 (100) | 1541 (100) | 255 (100) | 6907 (100) | 1185 (100) |
| Pre-admission aspirin use, No. (%) | | | | | | | | |
| Yes | 726 (18) | 154 (22) | 324 (22) | 59 (26) | 303 (20) | 60 (23) | 1353 (19) | 273 (23) |
| No | 2835 (72) | 468 (66) | 1058 (73) | 160 (70) | 1162 (75) | 188 (73) | 5055 (73) | 816 (69) |
| Unknown | 382 (10) | 82 (12) | 70 (5) | 10 (4) | 81 (5) | 8 (3) | 533 (8) | 100 (8) |

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | | | |
|---|-----------|-------------|------------|-------------|------------|-------------|------------|-------------|------------|------|--------|------|-----------|------|--------|------|--------|
| | Gender | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female |
| Total | | 3943 | 704 | 1452 | 229 | 3943 | 704 | 1452 | 229 | | | | | | | | |
| Pharmacological therapy given during admission, No. (%) | | | | | | | | | | | | | | | | | |
| Aspirin | | 3676 (93) | 642 (91) | 1364 (94) | 214 (93) | 1459 (94) | 244 (95) | 6499 (94) | 1100 (93) | | | | | | | | |
| ADP antagonist | | 2663 (68) | 491 (70) | 1134 (78) | 175 (76) | 1217 (79) | 194 (76) | 5014 (72) | 860 (72) | | | | | | | | |
| GP receptor inhibitor | | 143 (4) | 22 (3) | 75 (5) | 11 (5) | 52 (3) | 9 (4) | 270 (4) | 42 (4) | | | | | | | | |
| Unfractionated heparin | | 406 (10) | 69 (10) | 129 (9) | 25 (11) | 205 (13) | 39 (15) | 740 (11) | 133 (11) | | | | | | | | |
| LMWH | | 1310 (33) | 288 (41) | 613 (42) | 101 (44) | 649 (42) | 114 (45) | 2572 (37) | 503 (42) | | | | | | | | |
| Beta blocker | | 2533 (64) | 424 (60) | 885 (61) | 127 (55) | 875 (57) | 146 (57) | 4293 (62) | 697 (59) | | | | | | | | |
| ACE inhibitor | | 2268 (58) | 368 (52) | 792 (55) | 117 (51) | 798 (52) | 122 (48) | 3858 (56) | 607 (51) | | | | | | | | |
| Angiotensin II receptor blocker | | 178 (5) | 43 (6) | 95 (7) | 21 (9) | 92 (6) | 22 (9) | 365 (5) | 86 (7) | | | | | | | | |
| Statin | | 3552 (90) | 614 (87) | 1271 (88) | 197 (86) | 1398 (90) | 227 (89) | 6221 (90) | 1038 (87) | | | | | | | | |
| Other lipid lowering agent | | 163 (4) | 27 (4) | 118 (8) | 24 (10) | 65 (4) | 11 (4) | 346 (5) | 62 (5) | | | | | | | | |
| Diuretics | | 944 (24) | 243 (35) | 257 (18) | 68 (30) | 321 (21) | 84 (33) | 1522 (22) | 395 (33) | | | | | | | | |
| Calcium antagonist | | 258 (7) | 60 (9) | 90 (6) | 19 (8) | 70 (5) | 24 (9) | 418 (6) | 103 (9) | | | | | | | | |
| Oral hypoglycaemic agent | | 843 (21) | 210 (30) | 290 (20) | 66 (29) | 318 (21) | 61 (24) | 1451 (21) | 337 (28) | | | | | | | | |
| Insulin | | 860 (22) | 294 (42) | 285 (20) | 64 (28) | 338 (22) | 97 (38) | 1483 (21) | 455 (38) | | | | | | | | |
| Anti-arrhythmic agent | | 295 (7) | 64 (9) | 65 (4) | 13 (6) | 118 (8) | 31 (12) | 478 (7) | 108 (9) | | | | | | | | |

*Total admission days is derived as Outcome date – Admission date + 1

**Not given-Others' includes missing and refusal
Note: Percentage is to the nearest decimal point

Table 4.4 Treatments for patients with STEMI by ethnic group, NCVD-ACS Registry, 2006-2010

| Year | Ethnic group | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | | |
|----------------------------|--------------|------------|------------|------------|------------|------------|------------|------------|-------------|------------|------------|------------|-------------|-------------|-------------|------------|-----------|
| | | Malay | Chinese* | Indian | Others* | Malay | Chinese* | Indian | Others* | Malay | Chinese* | Indian | Others* | Malay | Chinese* | Indian | Others* |
| Total | 2515 | 958 | 874 | 300 | 932 | 318 | 331 | 100 | 1019 | 338 | 297 | 148 | 4466 | 1614 | 1502 | 548 | |
| Total admission days** | | | | | | | | | | | | | | | | | |
| N | 2387 | 903 | 829 | 241 | 892 | 303 | 316 | 91 | 904 | 275 | 255 | 102 | 4183 | 1481 | 1400 | 434 | |
| Mean (SD) | 6 (3) | 6 (3) | 6 (4) | 6 (3) | 5 (3) | 6 (3) | 6 (3) | 6 (2) | 6 (4) | 6 (4) | 6 (3) | 6 (3) | 6 (3) | 6 (3) | 6 (3) | 6 (3) | 6 (3) |
| Median (min, max) | 5 (1, 30) | 5 (1, 28) | 5 (1, 29) | 5 (1, 27) | 5 (1, 30) | 5 (1, 25) | 5 (1, 29) | 5 (1, 15) | 5 (1, 28) | 5 (1, 30) | 5 (1, 30) | 5 (1, 20) | 5 (1, 30) | 5 (1, 28) | 5 (1, 30) | 5 (1, 27) | 5 (1, 30) |
| IQR | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 1 | 2 | 3 | 2 | 1 | 2 | |
| Number of days on CCU | | | | | | | | | | | | | | | | | |
| N | 1923 | 680 | 552 | 204 | 690 | 233 | 222 | 75 | 726 | 220 | 172 | 105 | 3339 | 1133 | 946 | 384 | |
| Mean (SD) | 3 (3) | 3 (2) | 4 (3) | 3 (3) | 3 (2) | 3 (3) | 3 (2) | 3 (2) | 3 (3) | 4 (2) | 3 (2) | 4 (2) | 3 (3) | 3 (2) | 3 (3) | 3 (2) | 3 (3) |
| Median (min, max) | 3 (1, 28) | 3 (1, 17) | 3 (1, 29) | 3 (1, 28) | 3 (1, 14) | 3 (1, 24) | 3 (1, 21) | 3 (1, 11) | 3 (1, 30) | 3 (1, 14) | 3 (1, 14) | 3 (1, 20) | 3 (1, 30) | 3 (1, 24) | 3 (1, 29) | 3 (1, 28) | 3 (1, 29) |
| IQR | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | |
| Number of days on ICU/CICU | | | | | | | | | | | | | | | | | |
| N | 57 | 27 | 7 | 17 | 5 | 12 | 2 | 14 | 4 | 3 | 2 | 88 | 36 | 22 | 21 | | |
| Mean (SD) | 4 (4) | 3 (3) | 3 (1) | 2 (1) | 4 (2) | 2 (0) | 3 (1) | 10 (6) | 3 (1) | 2 (1) | 1 (1) | 3 (0) | 4 (3) | 3 (3) | 3 (1) | 3 (3) | |
| Median (min, max) | 3 (1, 17) | 2 (1, 13) | 2 (1, 5) | 2 (1, 4) | 2 (1, 9) | 2 (2, 3) | 2 (2, 4) | 2 (6, 14) | 3 (1, 5) | 3 (1, 5) | 3 (1, 2) | 3 (3, 3) | 2 (1, 17) | 2 (1, 13) | 2 (1, 5) | 2 (1, 14) | |
| IQR | 3 | 3 | 2 | 1 | 2 | 0 | 2 | 8 | 2 | 1 | 0 | 3 | 2 | 2 | 1 | | |

| Year | Ethnic group | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | | |
|---|--------------|------------|------------|------------|------------|------------|------------|------------|-------------|------------|------------|------------|-------------|-------------|-------------|------------|---------|
| | | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* |
| Total | 2515 | 958 | 874 | 300 | 932 | 318 | 331 | 100 | 1019 | 338 | 297 | 148 | 4466 | 1614 | 1502 | 548 | |
| Fibrinolytic therapy, No. (%) | 1906 (76) | 637 (66) | 623 (71) | 211 (70) | 726 (78) | 214 (67) | 246 (74) | 72 (72) | 773 (76) | 238 (70) | 215 (72) | 121 (82) | 3405 (76) | 1089 (67) | 1084 (72) | 404 (74) | |
| Given | 135 (5) | 88 (9) | 72 (8) | 24 (5) | 43 (7) | 21 (6) | 19 (7) | 7 (7) | 77 (8) | 32 (9) | 28 (9) | 3 (2) | 255 (6) | 141 (9) | 119 (6) | 34 (6) | |
| Not given-proceeded directly to primary angioplasty | 97 (4) | 46 (5) | 25 (3) | 20 (7) | 42 (5) | 19 (6) | 11 (3) | 10 (10) | 33 (3) | 18 (5) | 7 (5) | 6 (4) | 172 (4) | 83 (4) | 43 (5) | 36 (3) | |
| Not given-Contraindicated | 289 (11) | 145 (15) | 122 (14) | 31 (10) | 97 (10) | 49 (10) | 46 (15) | 9 (14) | 112 (9) | 37 (11) | 39 (11) | 14 (13) | 498 (9) | 231 (11) | 207 (14) | 54 (10) | |
| Not given-Missed thrombolysis | 88 (3) | 42 (4) | 32 (4) | 14 (5) | 24 (3) | 15 (5) | 9 (3) | 2 (2) | 24 (2) | 13 (4) | 8 (3) | 4 (3) | 136 (3) | 70 (3) | 49 (4) | 20 (4) | |
| Not given-Others*** | 1906 (76) | 637 (66) | 623 (71) | 211 (70) | 726 (78) | 214 (67) | 246 (74) | 72 (72) | 773 (76) | 238 (70) | 215 (72) | 121 (82) | 3405 (76) | 1089 (67) | 1084 (72) | 404 (74) | |
| Cardiac catheterisation, No. (%) | | | | | | | | | | | | | | | | | |
| Yes | 437 (17) | 239 (25) | 196 (22) | 68 (23) | 194 (21) | 104 (33) | 104 (31) | 23 (23) | 216 (21) | 81 (24) | 72 (24) | 10 (7) | 847 (19) | 424 (19) | 372 (26) | 101 (25) | |
| No | 2004 (80) | 691 (72) | 656 (75) | 211 (70) | 705 (65) | 208 (64) | 213 (65) | 65 (65) | 763 (69) | 234 (72) | 213 (72) | 124 (84) | 3472 (78) | 1133 (70) | 1082 (78) | 400 (73) | |
| Number transferred to another centre | 74 (3) | 28 (3) | 22 (3) | 21 (7) | 33 (4) | 6 (2) | 14 (4) | 12 (4) | 40 (12) | 23 (7) | 12 (4) | 14 (9) | 147 (3) | 57 (4) | 48 (3) | 47 (9) | |
| Percutaneous Coronary Intervention, No. (%) | | | | | | | | | | | | | | | | | |
| Yes | 389 (15) | 217 (23) | 194 (22) | 56 (19) | 145 (16) | 93 (29) | 84 (25) | 19 (19) | 137 (13) | 68 (20) | 58 (20) | 12 (8) | 671 (15) | 378 (15) | 336 (23) | 87 (22) | |
| No | 2126 (85) | 741 (77) | 680 (78) | 244 (81) | 787 (84) | 225 (71) | 247 (75) | 81 (81) | 882 (87) | 270 (80) | 239 (80) | 136 (85) | 3795 (92) | 1236 (85) | 1166 (77) | 461 (84) | |

| Year | Ethnic group | 2009 | | | | | | 2010 | | | | | | 2006-2010 | | | |
|---|----------------------|-------------|------------|------------|------------|------------|------------|------------|------------|-------------|------------|------------|------------|-------------|-------------|-------------|------------|
| | | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* |
| Total | CABG, No. (%) | 2515 | 958 | 874 | 300 | 932 | 318 | 331 | 100 | 1019 | 338 | 297 | 148 | 4466 | 1614 | 1502 | 548 |
| Yes | | 18 (1) | 8 (1) | 2 (0) | 0 (0) | 2 (0) | 1 (0) | 1 (0) | 0 (0) | 2 (0) | 2 (0) | 1 (0) | 1 (1) | 22 (0) | 11 (1) | 4 (0) | 1 (0) |
| No | | 2497 (99) | 950 (99) | 872 (100) | 300 (100) | 930 (100) | 317 (100) | 330 (100) | 100 (100) | 1017 (100) | 336 (99) | 296 (100) | 147 (99) | 4444 (100) | 1603 (99) | 1498 (100) | 547 (100) |
| Pre-admission aspirin use, No. (%) | | | | | | | | | | | | | | | | | |
| Yes | | 471 (19) | 170 (18) | 203 (23) | 36 (12) | 198 (21) | 69 (22) | 107 (32) | 9 (9) | 200 (20) | 61 (18) | 86 (29) | 16 (11) | 869 (19) | 300 (19) | 396 (26) | 61 (11) |
| No | | 1820 (72) | 691 (65) | 567 (73) | 225 (75) | 684 (73) | 237 (64) | 211 (86) | 86 (76) | 773 (78) | 263 (63) | 186 (86) | 128 (73) | 3277 (74) | 1191 (74) | 964 (64) | 439 (80) |
| Unknown | | 224 (9) | 97 (10) | 104 (12) | 39 (13) | 50 (5) | 12 (4) | 13 (5) | 5 (4) | 46 (5) | 14 (5) | 25 (4) | 4 (3) | 320 (7) | 123 (8) | 142 (9) | 48 (9) |
| Pharmacological therapy given during admission, No. (%) | | | | | | | | | | | | | | | | | |
| Aspirin | | 2339 (93) | 895 (93) | 816 (93) | 268 (89) | 877 (94) | 296 (93) | 314 (95) | 91 (91) | 960 (94) | 322 (95) | 283 (95) | 138 (93) | 4176 (94) | 1513 (94) | 1413 (94) | 497 (91) |
| ADP antagonist | | 1680 (67) | 723 (75) | 590 (68) | 161 (54) | 695 (75) | 270 (85) | 275 (83) | 69 (69) | 797 (78) | 265 (78) | 241 (81) | 108 (73) | 3172 (71) | 1258 (78) | 1106 (74) | 338 (62) |
| GP receptor inhibitor | | 91 (4) | 33 (3) | 29 (3) | 12 (4) | 40 (4) | 17 (5) | 25 (4) | 4 (8) | 37 (4) | 10 (4) | 9 (3) | 5 (3) | 168 (3) | 60 (4) | 63 (4) | 21 (4) |
| Unfractionated heparin | | 283 (11) | 71 (7) | 101 (12) | 20 (7) | 71 (8) | 36 (11) | 34 (10) | 13 (13) | 139 (14) | 45 (13) | 45 (15) | 15 (10) | 493 (11) | 152 (11) | 180 (9) | 48 (12) |
| LMWH | | 795 (32) | 327 (34) | 351 (40) | 125 (42) | 357 (38) | 136 (43) | 149 (45) | 72 (72) | 385 (38) | 147 (46) | 138 (43) | 93 (63) | 1537 (34) | 610 (38) | 638 (42) | 290 (53) |
| Beta blocker | | 1574 (63) | 654 (68) | 577 (66) | 152 (51) | 567 (61) | 182 (57) | 203 (61) | 60 (60) | 565 (55) | 198 (59) | 180 (61) | 78 (53) | 2706 (61) | 1034 (61) | 960 (64) | 290 (53) |

| Year | Ethnic group | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | | |
|---------------------------------|--------------|-------------|-------------|-------------|-------------|-------------|-------------|------------|-------------|-------------|-------------|-------------|--------------|--------------|--------------|-------------|---------|
| | | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* |
| Total | 2515 | 958 | 874 | 300 | 932 | 318 | 331 | 100 | 1019 | 338 | 297 | 148 | 4466 | 1614 | 1502 | 548 | |
| ACE inhibitor | 1472 (59) | 509 (60) | 523 (44) | 132 (57) | 528 (49) | 157 (50) | 165 (59) | 59 (53) | 542 (51) | 174 (48) | 144 (41) | 60 (41) | 2542 (57) | 840 (52) | 832 (55) | 251 (46) | |
| Angiotensin II receptor blocker | 107 (4) | 52 (5) | 45 (6) | 17 (7) | 62 (5) | 16 (10) | 33 (5) | 5 (6) | 59 (6) | 20 (10) | 29 (4) | 6 (5) | 228 (5) | 88 (5) | 107 (7) | 28 (5) | |
| Statin | 2259 (90) | 869 (91) | 775 (89) | 263 (88) | 808 (87) | 277 (87) | 288 (87) | 95 (95) | 926 (91) | 304 (90) | 262 (88) | 133 (90) | 3993 (89) | 1450 (90) | 1325 (88) | 491 (90) | |
| Other lipid lowering agent | 104 (4) | 34 (4) | 43 (5) | 9 (3) | 90 (10) | 16 (5) | 29 (9) | 7 (7) | 31 (7) | 21 (3) | 13 (6) | 11 (4) | 225 (7) | 71 (5) | 85 (4) | 27 (6) | |
| Diuretics | 673 (27) | 208 (22) | 236 (27) | 70 (23) | 198 (21) | 52 (16) | 53 (16) | 22 (22) | 229 (22) | 68 (20) | 67 (23) | 41 (28) | 1100 (25) | 328 (25) | 356 (20) | 133 (24) | |
| Calcium antagonist | 169 (7) | 60 (6) | 67 (8) | 22 (7) | 63 (7) | 14 (4) | 27 (8) | 5 (5) | 56 (5) | 11 (3) | 23 (8) | 4 (3) | 288 (3) | 85 (3) | 117 (5) | 31 (6) | |
| Oral hypoglycaemic agent | 529 (21) | 199 (21) | 289 (33) | 36 (12) | 181 (19) | 58 (18) | 105 (32) | 12 (12) | 218 (21) | 50 (15) | 96 (32) | 15 (10) | 928 (10) | 307 (10) | 490 (19) | 63 (33) | |
| Insulin | 604 (24) | 205 (21) | 300 (34) | 45 (15) | 200 (21) | 49 (15) | 90 (27) | 10 (10) | 255 (25) | 63 (19) | 98 (33) | 19 (13) | 1059 (13) | 317 (24) | 488 (20) | 74 (32) | |
| Anti-arrhythmic agent | 181 (7) | 84 (9) | 63 (7) | 31 (10) | 42 (5) | 13 (4) | 11 (3) | 12 (12) | 80 (8) | 26 (8) | 29 (10) | 14 (9) | 303 (7) | 123 (7) | 103 (8) | 57 (10) | |

*Total admission days is derived as Outcome date - Admission date + 1

**'Not given-Others' includes missing and refusal
Note: Percentage is to the nearest decimal point

Table 4.5 Door to needle and balloon time distribution for patients with STEMI by year, NCVD-ACS Registry, 2006-2010

| ACS stratum | STEMI only | | | 2009 | 2010 | 2006-2010 |
|----------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| | 2006 | 2007 | 2008 | | | |
| Door to needle time, min | | | | | | |
| N | 745 | 827 | 794 | 832 | 921 | 4119 |
| Mean (SD) | 103 (143) | 91 (131) | 112 (195) | 100 (186) | 119 (217) | 105 (179) |
| Median (min, max) | 60 (2, 1349) | 53 (1, 1435) | 50 (1, 1440) | 45 (2, 1440) | 45 (3, 1440) | 50 (1, 1440) |
| IQR | 90 | 70 | 72 | 68 | 73 | 75 |
| Door to balloon time, min | | | | | | |
| N | 151 | 126 | 99 | 134 | 123 | 633 |
| Mean (SD) | 237 (292) | 215 (266) | 214 (260) | 265 (338) | 192 (224) | 226 (281) |
| Median (min, max) | 133 (35, 1440) | 112 (25, 1410) | 114 (11, 1195) | 119 (24, 1391) | 108 (13, 1410) | 117 (11, 1440) |
| IQR | 135 | 154 | 139 | 186 | 134 | 153 |

Table 4.6 Treatments for patients with NSTEMI/UA by age group (years), NCVD-ACS Registry, 2006-2010

| Year | 2006-2008 | | | 2009 | | | 2010 | | | 2006-2010 | | |
|----------------------------|------------|-------------|-------------|-----------|------------|-------------|-----------|------------|------------|------------|-------------|-------------|
| Age group* | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly |
| Total | 172 | 2238 | 2814 | 58 | 798 | 1057 | 66 | 683 | 850 | 296 | 3719 | 4721 |
| Total admission days** | | | | | | | | | | | | |
| N | 163 | 2141 | 2667 | 58 | 784 | 1020 | 59 | 623 | 753 | 280 | 3548 | 4440 |
| Mean (SD) | 5 (2) | 5 (4) | 6 (4) | 5 (3) | 5 (3) | 6 (4) | 5 (4) | 5 (3) | 5 (4) | 5 (3) | 5 (3) | 6 (4) |
| Median (min, max) | 4 (2, 17) | 4 (1, 30) | 5 (1, 30) | 4 (1, 13) | 4 (1, 28) | 4 (1, 30) | 4 (2, 26) | 4 (1, 24) | 4 (1, 30) | 4 (1, 26) | 4 (1, 30) | 5 (1, 30) |
| IQR | 2 | 3 | 3 | 2 | 3 | 4 | 3 | 2 | 4 | 2 | 3 | 4 |
| Number of days on CCU | | | | | | | | | | | | |
| N | 49 | 604 | 802 | 25 | 364 | 472 | 15 | 132 | 190 | 89 | 1100 | 1464 |
| Mean (SD) | 2 (2) | 3 (3) | 4 (3) | 3 (3) | 3 (3) | 4 (4) | 4 (4) | 4 (2) | 3 (2) | 4 (3) | 3 (3) | 4 (3) |
| Median (min, max) | 2 (1, 10) | 3 (1, 24) | 3 (1, 30) | 2 (1, 12) | 3 (1, 26) | 3 (1, 30) | 4 (1, 8) | 3 (1, 10) | 3 (1, 16) | 2 (1, 12) | 3 (1, 26) | 3 (1, 30) |
| IQR | 2 | 3 | 2 | 3 | 2 | 3 | 4 | 2 | 3 | 3 | 2 | 2 |
| Number of days on ICU/CICU | | | | | | | | | | | | |
| N | 3 | 81 | 111 | 0 | 9 | 19 | 1 | 10 | 8 | 4 | 100 | 138 |
| Mean (SD) | 2 (2) | 3 (2) | 4 (3) | . | 2 (1) | 5 (6) | 1 (.) | 3 (1) | 4 (3) | 2 (2) | 3 (2) | 4 (4) |
| Median (min, max) | 1 (1, 4) | 3 (1, 12) | 3 (1, 24) | . | 2 (1, 4) | 3 (1, 24) | 1 (1, 1) | 3 (2, 4) | 3 (1, 8) | 1 (1, 4) | 2 (1, 12) | 3 (1, 24) |
| IQR | 3 | 3 | 2 | . | 1 | 4 | 0 | 2 | 4 | 2 | 2 | 2 |

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | |
|---|------------|-------------|-------------|-----------|------------|-------------|-----------|------------|------------|------------|-------------|-------------|-----------|------------|
| | Age group* | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Young | Middle-age |
| Total | 172 | 2238 | 2814 | 58 | 798 | 1057 | 66 | 683 | 850 | 296 | 3719 | 4721 | | |
| Cardiac catheterisation, No. (%) | | | | | | | | | | | | | | |
| Yes | 34 (20) | 436 (19) | 449 (16) | 8 (14) | 145 (18) | 178 (17) | 8 (12) | 88 (13) | 128 (15) | 50 (17) | 669 (18) | 755 (16) | | |
| No | 137 (80) | 1762 (79) | 2307 (82) | 50 (86) | 638 (80) | 862 (82) | 53 (80) | 568 (83) | 690 (81) | 240 (81) | 2968 (80) | 3859 (82) | | |
| Number transferred to another centre | 1 (1) | 40 (2) | 58 (2) | . | 15 (2) | 17 (2) | 5 (8) | 27 (4) | 32 (4) | 6 (2) | 82 (2) | 107 (2) | | |
| Percutaneous Coronary Intervention, No. (%) | | | | | | | | | | | | | | |
| Yes | 25 (15) | 280 (13) | 277 (10) | 5 (9) | 84 (11) | 89 (8) | 7 (11) | 50 (7) | 66 (8) | 37 (13) | 414 (11) | 432 (9) | | |
| No | 147 (85) | 1958 (87) | 2537 (90) | 53 (91) | 714 (89) | 968 (92) | 59 (89) | 633 (93) | 784 (92) | 259 (88) | 3305 (89) | 4289 (91) | | |
| CABG, No. (%) | | | | | | | | | | | | | | |
| Yes | 1 (1) | 44 (2) | 67 (2) | 0 (0) | 9 (1) | 19 (2) | 0 (0) | 6 (1) | 6 (1) | 1 (0) | 59 (2) | 92 (2) | | |
| No | 171 (99) | 2194 (98) | 2747 (98) | 58 (100) | 789 (99) | 1038 (98) | 66 (100) | 677 (99) | 844 (99) | 295 (100) | 3660 (98) | 4629 (98) | | |
| Pre-admission aspirin use, No. (%) | | | | | | | | | | | | | | |
| Yes | 56 (33) | 955 (43) | 1382 (49) | 18 (31) | 398 (50) | 580 (55) | 24 (36) | 314 (46) | 413 (49) | 98 (33) | 1667 (45) | 2375 (50) | | |
| No | 84 (49) | 976 (44) | 1040 (37) | 39 (67) | 383 (48) | 455 (43) | 39 (59) | 332 (49) | 394 (46) | 162 (55) | 1691 (45) | 1889 (40) | | |
| Unknown | 32 (19) | 307 (14) | 392 (14) | 1 (2) | 17 (2) | 22 (2) | 3 (5) | 37 (5) | 43 (5) | 36 (12) | 361 (10) | 457 (10) | | |
| | | | | | | | | | | | | | | |

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | |
|---|------------|-------------|-------------|-----------|------------|-------------|-----------|------------|------------|------------|-------------|-------------|-----------|--|--|
| | Age group* | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly | Young | Middle-age | Elderly | | |
| Total | 172 | 2238 | 2814 | 58 | 798 | 1057 | 66 | 683 | 850 | 296 | 3719 | 4721 | | | |
| Pharmacological therapy given during admission, No. (%) | | | | | | | | | | | | | | | |
| Aspirin | 152 (88) | 1992 (89) | 2429 (86) | 54 (93) | 759 (95) | 980 (93) | 62 (94) | 630 (92) | 767 (90) | 268 (91) | 3381 (91) | 4176 (88) | | | |
| ADP antagonist | 92 (53) | 1258 (56) | 1716 (61) | 41 (71) | 645 (81) | 872 (82) | 48 (73) | 485 (71) | 646 (76) | 181 (61) | 2388 (64) | 3234 (69) | | | |
| GP receptor inhibitor | 5 (3) | 55 (2) | 68 (2) | 1 (2) | 11 (1) | 13 (1) | 2 (3) | 16 (2) | 25 (3) | 8 (3) | 82 (2) | 106 (2) | | | |
| Unfractionated heparin | 27 (16) | 339 (15) | 329 (12) | 4 (7) | 41 (5) | 71 (7) | 4 (6) | 56 (8) | 67 (8) | 35 (12) | 436 (12) | 467 (10) | | | |
| LMWH | 118 (69) | 1537 (69) | 1977 (70) | 46 (79) | 671 (84) | 880 (83) | 48 (73) | 513 (75) | 631 (74) | 212 (72) | 2721 (73) | 3488 (74) | | | |
| Beta blocker | 114 (66) | 1533 (68) | 1815 (64) | 38 (66) | 536 (67) | 707 (67) | 34 (52) | 439 (64) | 510 (60) | 186 (63) | 2508 (67) | 3032 (64) | | | |
| ACE inhibitor | 99 (58) | 1322 (59) | 1546 (55) | 31 (53) | 533 (67) | 627 (59) | 32 (48) | 377 (55) | 423 (50) | 162 (55) | 2232 (60) | 2596 (55) | | | |
| Angiotensin II receptor blocker | 9 (5) | 180 (8) | 321 (11) | 6 (10) | 65 (8) | 135 (13) | 5 (8) | 62 (9) | 124 (15) | 20 (7) | 307 (8) | 580 (12) | | | |
| Statins | 148 (86) | 1980 (88) | 2426 (86) | 51 (88) | 672 (84) | 902 (85) | 58 (88) | 602 (88) | 749 (88) | 257 (87) | 3254 (87) | 4077 (86) | | | |
| Other lipid lowering agent | 13 (8) | 142 (6) | 166 (6) | 7 (12) | 54 (7) | 74 (7) | 5 (8) | 36 (5) | 58 (7) | 25 (8) | 232 (6) | 298 (6) | | | |
| Diuretics | 34 (20) | 597 (27) | 1149 (41) | 10 (17) | 172 (22) | 394 (37) | 15 (23) | 190 (28) | 354 (42) | 59 (20) | 959 (26) | 1897 (40) | | | |
| Calcium antagonist | 22 (13) | 373 (17) | 720 (26) | 4 (7) | 129 (16) | 215 (20) | 11 (17) | 118 (17) | 237 (28) | 37 (13) | 620 (17) | 1172 (25) | | | |
| Oral hypoglycaemic agent | 35 (20) | 653 (29) | 856 (30) | 12 (21) | 284 (36) | 308 (29) | 10 (15) | 204 (30) | 250 (29) | 57 (19) | 1141 (31) | 1414 (30) | | | |
| Insulin | 23 (13) | 527 (24) | 701 (25) | 5 (9) | 183 (23) | 224 (21) | 10 (15) | 166 (24) | 218 (26) | 38 (13) | 876 (24) | 1143 (24) | | | |
| Anti-arrhythmic agent | 6 (3) | 106 (5) | 212 (8) | 1 (2) | 33 (4) | 84 (8) | 2 (3) | 27 (4) | 67 (8) | 9 (3) | 166 (4) | 363 (8) | | | |

*Young is defined as age from 20 to less than 40 years, middle-age is defined as age between 40 to less than 60 years and elderly is defined as 60 years and above

**Total admission days is derived as Outcome date – Admission date + 1

Note: Percentage is to the nearest decimal point

Table 4.7 Treatments for patients with NSTEMI/UA by gender, NCVD-ACS Registry, 2006-2010

| Year | 2006-2008 | | 2009 | | 2010 | | 2006-2010 | |
|--------------------------------------|-------------|-------------|-------------|------------|-------------|------------|-------------|-------------|
| Gender | Male | Female | Male | Female | Male | Female | Male | Female |
| Total | 3533 | 1691 | 1274 | 639 | 1075 | 524 | 5882 | 2854 |
| Total admission days* | | | | | | | | |
| N | 3375 | 1596 | 1243 | 619 | 962 | 473 | 5580 | 2688 |
| Mean (SD) | 6 (4) | 6 (4) | 5 (4) | 5 (4) | 5 (4) | 5 (3) | 6 (4) | 6 (4) |
| Median (min, max) | 4 (1, 30) | 5 (1, 30) | 4 (1, 30) | 4 (1, 29) | 4 (1, 30) | 4 (1, 23) | 4 (1, 30) | 4 (1, 30) |
| IQR | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 |
| Number of days on CCU | | | | | | | | |
| N | 1068 | 387 | 587 | 274 | 241 | 96 | 1896 | 757 |
| Mean (SD) | 3 (3) | 4 (4) | 4 (3) | 4 (4) | 3 (2) | 4 (3) | 3 (3) | 4 (4) |
| Median (min, max) | 3 (1, 24) | 3 (1, 30) | 3 (1, 28) | 3 (1, 30) | 3 (1, 16) | 3 (1, 14) | 3 (1, 28) | 3 (1, 30) |
| IQR | 3 | 3 | 2 | 3 | 2 | 3 | 2 | 3 |
| Number of days on ICU/CICU | | | | | | | | |
| N | 142 | 53 | 26 | 2 | 12 | 7 | 180 | 62 |
| Mean (SD) | 3 (3) | 4 (4) | 4 (5) | 2 (0) | 2 (1) | 4 (3) | 3 (3) | 4 (4) |
| Median (min, max) | 2 (1, 24) | 3 (1, 23) | 3 (1, 24) | 2 (2, 2) | 2 (1, 4) | 4 (1, 8) | 2 (1, 24) | 3 (1, 23) |
| IQR | 3 | 3 | 3 | 0 | 1 | 5 | 3 | 3 |
| Cardiac catheterisation, No. (%) | | | | | | | | |
| Yes | 679 (19) | 240 (14) | 260 (20) | 71 (11) | 164 (15) | 60 (11) | 1103 (19) | 371 (13) |
| No | 2790 (79) | 1416 (84) | 990 (78) | 560 (88) | 866 (81) | 445 (85) | 4646 (79) | 2421 (85) |
| Number transferred to another centre | 64 (2) | 35 (2) | 24 (2) | 8 (1) | 45 (4) | 19 (4) | 133 (2) | 62 (2) |

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | |
|---|------------------|---------------|-------------|---------------|-------------|---------------|-------------|---------------|-------------|---------------|-------------|---------------|------------------|-------------|
| Gender | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Total | 2854 |
| Total | 3533 | 1691 | 1274 | 639 | 1075 | 524 | 5882 | 2854 | | | | | | |
| Percutaneous Coronary Intervention, No. (%) | | | | | | | | | | | | | | |
| Yes | 433 (12) | 149 (9) | 139 (11) | 39 (6) | 93 (9) | 30 (6) | 665 (11) | 218 (8) | | | | | | |
| No | 3100 (88) | 1542 (91) | 1135 (89) | 600 (94) | 982 (91) | 494 (94) | 5217 (89) | 2636 (92) | | | | | | |
| CABG, No. (%) | | | | | | | | | | | | | | |
| Yes | 87 (2) | 25 (1) | 25 (2) | 3 (0) | 10 (1) | 2 (0) | 122 (2) | 30 (1) | | | | | | |
| No | 3446 (98) | 1666 (99) | 1249 (98) | 636 (100) | 1065 (99) | 522 (100) | 5760 (98) | 2824 (99) | | | | | | |
| Pre-admission aspirin use, No. (%) | | | | | | | | | | | | | | |
| Yes | 1651 (47) | 742 (44) | 673 (53) | 323 (51) | 528 (49) | 223 (43) | 2852 (48) | 1288 (45) | | | | | | |
| No | 1376 (39) | 724 (43) | 577 (45) | 300 (47) | 494 (46) | 271 (52) | 2447 (42) | 1295 (45) | | | | | | |
| Unknown | 506 (14) | 225 (13) | 24 (2) | 16 (3) | 53 (5) | 30 (6) | 583 (10) | 271 (9) | | | | | | |
| Pharmacological therapy given during admission, No. (%) | | | | | | | | | | | | | | |
| Aspirin | 3131 (89) | 1442 (85) | 1201 (94) | 592 (93) | 992 (92) | 467 (89) | 5324 (91) | 2501 (88) | | | | | | |
| ADP antagonist | 2132 (60) | 934 (55) | 1055 (83) | 503 (79) | 804 (75) | 375 (72) | 3991 (68) | 1812 (63) | | | | | | |
| GP receptor inhibitor | 94 (3) | 34 (2) | 19 (1) | 6 (1) | 28 (3) | 15 (3) | 141 (2) | 55 (2) | | | | | | |
| Unfractionated heparin | 483 (14) | 212 (13) | 81 (6) | 35 (5) | 87 (8) | 40 (8) | 651 (11) | 287 (10) | | | | | | |
| LMWH | 2430 (69) | 1202 (71) | 1045 (82) | 552 (86) | 799 (74) | 393 (75) | 4274 (73) | 2147 (75) | | | | | | |
| Beta blocker | 2379 (67) | 1083 (64) | 864 (68) | 417 (65) | 670 (62) | 313 (60) | 3913 (67) | 1813 (64) | | | | | | |
| ACE inhibitor | 2072 (59) | 895 (53) | 810 (64) | 381 (60) | 572 (53) | 260 (50) | 3454 (59) | 1536 (54) | | | | | | |
| Angiotensin II receptor blocker | 307 (9) | 203 (12) | 136 (11) | 70 (11) | 116 (11) | 75 (14) | 559 (10) | 348 (12) | | | | | | |

| Year | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | | |
|----------------------------|-------------|-------------|-------------|------------|-------------|------------|------------|-------------|------|--------|------|--------|-----------|--------|------|--------|
| Gender | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female |
| Total | 3533 | 1691 | 1274 | 639 | 1075 | 524 | 582 | 2854 | | | | | | | | |
| Statin | 3089 (87) | 1465 (87) | 1081 (85) | 544 (85) | 953 (89) | 456 (87) | 5123 (87) | 2465 (86) | | | | | | | | |
| Other lipid lowering agent | 214 (6) | 107 (6) | 96 (8) | 39 (6) | 69 (6) | 30 (6) | 379 (6) | 176 (6) | | | | | | | | |
| Diuretics | 1120 (32) | 660 (39) | 355 (28) | 221 (35) | 359 (33) | 200 (38) | 1834 (31) | 1081 (38) | | | | | | | | |
| Calcium antagonist | 656 (19) | 459 (27) | 208 (16) | 140 (22) | 223 (21) | 143 (27) | 1087 (18) | 742 (26) | | | | | | | | |
| Oral hypoglycaemic agent | 946 (27) | 598 (35) | 382 (30) | 222 (35) | 302 (28) | 162 (31) | 1630 (28) | 982 (34) | | | | | | | | |
| Insulin | 751 (21) | 500 (30) | 240 (19) | 172 (27) | 253 (24) | 141 (27) | 1244 (21) | 813 (28) | | | | | | | | |
| Anti-arrhythmic agent | 217 (6) | 107 (6) | 76 (6) | 42 (7) | 62 (6) | 34 (6) | 355 (6) | 183 (6) | | | | | | | | |

*Total admission days is derived as Outcome date – Admission date + 1

Note: Percentage is to the nearest decimal point

Table 4.8 Treatments for patients with NSTEMI/UA by ethnic group, NCVD-ACS Registry, 2006-2010

| Year | Ethnic group | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | |
|----------------------------|--------------|-------------|------------|------------|------------|------------|-----------|------------|------------|------------|-----------|-------------|-------------|-------------|------------|
| | | Malay | Chinese | Others* | Indian | Malay | Chinese | Others* | Indian | Malay | Chinese | Others* | Indian | Malay | Chinese |
| Total | 2304 | 1337 | 216 | 855 | 446 | 535 | 77 | 693 | 359 | 483 | 64 | 3852 | 2142 | 2385 | 357 |
| Total admission days** | | | | | | | | | | | | | | | |
| N | 2198 | 1279 | 1304 | 190 | 838 | 432 | 519 | 73 | 627 | 316 | 443 | 49 | 3663 | 2027 | 2266 |
| Mean (SD) | 6 (4) | 5 (4) | 6 (4) | 6 (4) | 5 (3) | 5 (4) | 6 (5) | 5 (4) | 5 (2) | 5 (3) | 5 (3) | 6 (4) | 5 (4) | 5 (4) | 6 (4) |
| Median (min, max) | 5 (1, 30) | 4 (1, 30) | 4 (1, 30) | 4 (2, 22) | 4 (1, 30) | 4 (1, 28) | 4 (1, 24) | 4 (1, 30) | 4 (1, 19) | 4 (1, 24) | 4 (1, 13) | 4 (1, 19) | 4 (1, 30) | 4 (1, 30) | 4 (1, 30) |
| IQR | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Number of days on CCU | | | | | | | | | | | | | | | |
| N | 728 | 378 | 234 | 115 | 369 | 189 | 248 | 55 | 188 | 61 | 73 | 15 | 1285 | 628 | 555 |
| Mean (SD) | 3 (3) | 3 (3) | 4 (3) | 3 (2) | 4 (4) | 3 (3) | 4 (3) | 3 (3) | 3 (2) | 4 (3) | 3 (2) | 4 (3) | 3 (3) | 4 (3) | 3 (2) |
| Median (min, max) | 3 (1, 30) | 2 (1, 24) | 3 (1, 21) | 2 (1, 14) | 2 (1, 28) | 3 (1, 21) | 2 (1, 28) | 3 (1, 30) | 3 (1, 14) | 3 (1, 12) | 3 (1, 10) | 3 (1, 16) | 3 (1, 7) | 3 (1, 30) | 3 (1, 24) |
| IQR | 2 | 3 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 3 | 2 | 2 | 3 | 3 |
| Number of days on ICU/CICU | | | | | | | | | | | | | | | |
| N | 89 | 60 | 20 | 26 | 13 | 4 | 5 | 6 | 12 | 2 | 3 | 2 | 114 | 66 | 28 |
| Mean (SD) | 4 (4) | 3 (2) | 4 (3) | 3 (2) | 4 (6) | 4 (3) | 3 (2) | 5 (7) | 3 (2) | 2 (1) | 4 (4) | 3 (1) | 4 (4) | 3 (2) | 3 (3) |
| Median (min, max) | 3 (1, 24) | 3 (1, 11) | 3 (1, 12) | 2 (1, 10) | 2 (1, 24) | 2 (1, 7) | 2 (1, 5) | 2 (1, 19) | 2 (1, 7) | 2 (1, 3) | 2 (1, 8) | 2 (1, 4) | 3 (1, 24) | 3 (1, 11) | 2 (1, 12) |
| IQR | 2 | 3 | 4 | 1 | 2 | 3 | 3 | 3 | 2 | 2 | 7 | 2 | 2 | 3 | 4 |

| Year | Ethnic group | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | | |
|---|--------------|-----------|-----------|----------|----------|----------|----------|---------|----------|----------|-----------|----------|-----------|-----------|-----------|----------|---------|
| | | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* | Malay | Chinese | Indian | Others* |
| Total | 2304 | 1337 | 1367 | 216 | 855 | 446 | 535 | 77 | 693 | 359 | 483 | 64 | 3852 | 2142 | 2385 | 357 | |
| Cardiac catheterisation, No. (%) | | | | | | | | | | | | | | | | | |
| Yes | 387 (17) | 221 (18) | 252 (18) | 59 (27) | 153 (13) | 60 (19) | 103 (19) | 15 (15) | 104 (15) | 36 (10) | 73 (15) | 11 (17) | 644 (17) | 317 (15) | 428 (18) | 85 (24) | |
| No | 1862 (81) | 1091 (82) | 1098 (80) | 155 (72) | 690 (81) | 375 (84) | 425 (79) | 60 (78) | 560 (81) | 306 (85) | 396 (82) | 49 (77) | 3112 (81) | 1772 (83) | 1919 (80) | 264 (74) | |
| Number transferred to another centre | 55 (2) | 25 (2) | 17 (1) | 2 (1) | 12 (1) | 7 (1) | 11 (2) | 2 (3) | 29 (4) | 17 (5) | 14 (3) | 4 (6) | 96 (2) | 53 (2) | 38 (2) | 8 (2) | |
| Percutaneous Coronary Intervention, No. (%) | | | | | | | | | | | | | | | | | |
| Yes | 240 (10) | 142 (11) | 166 (12) | 34 (16) | 73 (9) | 33 (7) | 65 (12) | 7 (9) | 50 (7) | 16 (4) | 49 (10) | 8 (4) | 363 (13) | 191 (9) | 280 (12) | 49 (14) | |
| No | 2064 (90) | 1195 (89) | 1201 (88) | 182 (84) | 782 (91) | 413 (93) | 470 (88) | 70 (91) | 643 (93) | 343 (96) | 434 (90) | 56 (88) | 3489 (91) | 1951 (91) | 2105 (91) | 308 (86) | |
| CABG, No. (%) | | | | | | | | | | | | | | | | | |
| Yes | 58 (3) | 30 (2) | 15 (1) | 9 (4) | 17 (2) | 3 (1) | 3 (1) | 5 (6) | 8 (1) | 2 (1) | 2 (0) | 0 (0) | 83 (2) | 35 (2) | 20 (1) | 14 (4) | |
| No | 2246 (97) | 1307 (98) | 1352 (99) | 207 (96) | 838 (98) | 443 (99) | 532 (99) | 72 (94) | 685 (99) | 357 (99) | 481 (100) | 64 (100) | 3769 (98) | 2107 (98) | 2365 (99) | 343 (96) | |
| Pre-admission aspirin use, No. (%) | | | | | | | | | | | | | | | | | |
| Yes | 1068 (46) | 568 (42) | 688 (50) | 69 (32) | 460 (54) | 224 (50) | 283 (53) | 29 (38) | 324 (47) | 155 (43) | 244 (51) | 28 (44) | 1852 (48) | 947 (44) | 1215 (51) | 126 (35) | |
| No | 954 (41) | 584 (44) | 442 (32) | 120 (56) | 377 (44) | 213 (48) | 244 (46) | 43 (56) | 335 (48) | 189 (53) | 213 (44) | 28 (43) | 1666 (44) | 986 (43) | 899 (46) | 191 (54) | |
| Unknown | 282 (12) | 185 (14) | 237 (17) | 27 (13) | 18 (2) | 9 (1) | 5 (2) | 34 (6) | 15 (5) | 26 (4) | 8 (5) | 334 (13) | 209 (9) | 271 (10) | 40 (11) | | |

| Year | Ethnic group | 2006-2008 | | | | 2009 | | | | 2010 | | | | 2006-2010 | | | |
|---|--------------|--------------|--------------|-------------|-------------|-------------|-------------|------------|-------------|-------------|-------------|------------|--------------|--------------|--------------|-------------|---------|
| | | Malay | Chinese* | Indian | Others* | Malay | Chinese* | Indian | Others* | Malay | Chinese* | Indian | Others* | Malay | Chinese* | Indian | Others* |
| Total | 2304 | 1337 | 1367 | 216 | 855 | 446 | 535 | 77 | 693 | 359 | 483 | 64 | 3852 | 2142 | 2385 | 357 | |
| Pharmacological therapy given during admission, No. (%) | | | | | | | | | | | | | | | | | |
| Aspirin | 2026 (88) | 1177 (88) | 1175 (86) | 195 (90) | 803 (94) | 411 (92) | 511 (96) | 68 (88) | 641 (92) | 324 (90) | 438 (91) | 56 (88) | 3470 (90) | 1912 (89) | 2124 (89) | 319 (89) | |
| ADP antagonist | 1258 (55) | 859 (64) | 814 (60) | 135 (63) | 651 (76) | 384 (86) | 463 (87) | 60 (78) | 499 (72) | 277 (77) | 364 (75) | 39 (61) | 2408 (63) | 1520 (71) | 1641 (69) | 234 (66) | |
| GP receptor inhibitor | 48 (2) | 40 (3) | 34 (2) | 6 (1) | 9 (1) | 10 (2) | 5 (1) | 1 (1) | 20 (1) | 9 (3) | 13 (3) | 1 (3) | 77 (2) | 59 (2) | 52 (3) | 8 (2) | |
| Unfractionated heparin | 472 (20) | 82 (6) | 129 (9) | 12 (8) | 66 (6) | 25 (3) | 16 (3) | 9 (12) | 65 (9) | 20 (9) | 34 (7) | 8 (6) | 603 (7) | 127 (13) | 179 (16) | 29 (6) | |
| LMWH | 1436 (62) | 1022 (76) | 1018 (74) | 156 (72) | 678 (79) | 392 (88) | 469 (88) | 58 (75) | 489 (71) | 373 (71) | 45 (77) | 45 (70) | 2603 (70) | 1699 (68) | 1860 (79) | 259 (78) | |
| Beta blocker | 1484 (64) | 934 (70) | 900 (66) | 144 (67) | 586 (69) | 288 (65) | 353 (66) | 54 (70) | 425 (61) | 216 (60) | 307 (61) | 35 (64) | 2495 (55) | 1438 (65) | 1560 (67) | 233 (65) | |
| ACE inhibitor | 1356 (59) | 729 (55) | 777 (57) | 105 (49) | 542 (63) | 284 (64) | 329 (61) | 36 (47) | 363 (52) | 170 (52) | 271 (47) | 28 (56) | 2261 (44) | 1183 (59) | 1377 (55) | 169 (47) | |
| Angiotensin II receptor blocker | 197 (9) | 139 (10) | 152 (11) | 22 (10) | 95 (11) | 34 (8) | 65 (12) | 12 (16) | 79 (11) | 42 (11) | 62 (12) | 8 (13) | 371 (13) | 215 (10) | 279 (10) | 42 (12) | |
| Statin | 1995 (87) | 1181 (88) | 1186 (87) | 192 (89) | 730 (85) | 377 (85) | 451 (84) | 67 (87) | 619 (89) | 310 (86) | 428 (89) | 52 (81) | 3344 (87) | 1868 (87) | 2065 (87) | 311 (87) | |
| Other lipid lowering agent | 148 (6) | 85 (6) | 79 (4) | 9 (4) | 56 (7) | 29 (7) | 43 (8) | 7 (9) | 43 (6) | 21 (6) | 27 (6) | 8 (13) | 247 (6) | 135 (6) | 149 (6) | 24 (7) | |
| Diuretics | 825 (36) | 437 (33) | 450 (31) | 68 (33) | 281 (31) | 114 (33) | 151 (26) | 30 (28) | 267 (39) | 116 (39) | 163 (32) | 13 (34) | 1373 (20) | 667 (36) | 764 (31) | 111 (31) | |
| Calcium antagonist | 487 (21) | 266 (20) | 321 (23) | 41 (19) | 161 (19) | 80 (18) | 90 (17) | 17 (22) | 146 (21) | 80 (22) | 130 (27) | 10 (16) | 794 (21) | 426 (20) | 541 (23) | 68 (19) | |
| Oral hypoglycaemic agent | 594 (26) | 354 (26) | 550 (40) | 46 (21) | 257 (30) | 124 (28) | 202 (38) | 21 (27) | 188 (27) | 78 (22) | 185 (38) | 13 (22) | 1039 (20) | 556 (27) | 937 (26) | 80 (22) | |
| Insulin | 500 (22) | 273 (20) | 441 (32) | 37 (17) | 196 (23) | 65 (15) | 142 (27) | 9 (12) | 153 (22) | 70 (19) | 161 (33) | 10 (16) | 849 (22) | 408 (19) | 744 (31) | 56 (16) | |
| Anti-arrhythmic agent | 144 (6) | 89 (7) | 69 (5) | 22 (10) | 59 (7) | 19 (4) | 11 (14) | 49 (7) | 24 (7) | 21 (4) | 2 (3) | 2 (7) | 109 (7) | 142 (4) | 109 (5) | 35 (10) | |

Table 4.9 Treatments for patients with ACS by type of participating centres, NCVD-ACS Registry, 2006-2010

| | 2006 | | | | 2007 | | | | 2008 | | | |
|---|-------------|--------------|-------------|--------------|-------------|--------------|-------------|--------------|-----------------|---------------------|------------------|-----------------|
| | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | Physical centre | Cardiologist centre | Physician centre | Physical centre |
| Caridiologist centre | | | | | | | | | | | | |
| Given | 614 (69) | 391 (74) | | | 573 (66) | 657 (80) | | | 513 (65) | 629 (85) | | |
| Not given – proceeded directly to primary angioplasty | 109 (12) | 7 (1) | | | 109 (13) | 4 (0) | | | 87 (11) | 3 (0) | | |
| Not given – Contraindicated | 35 (4) | 34 (6) | | | 31 (4) | 32 (4) | | | 26 (3) | 30 (4) | | |
| Not given – Missed thrombolysis | 109 (12) | 83 (16) | | | 132 (15) | 95 (12) | | | 107 (14) | 61 (8) | | |
| Not given – Others* | 29 (3) | 16 (3) | | | 23 (3) | 31 (4) | | | 59 (7) | 18 (2) | | |
| Percutaneous Coronary Intervention, No. (%) | | | | | | | | | | | | |
| Yes | 303 (34) | 0 (0) | 162 (20) | 0 (0) | 73 (12) | 0 (0) | 296 (34) | 0 (0) | 164 (25) | 0 (0) | 73 (12) | 0 (0) |
| No | 593 (66) | 531 (100) | 665 (80) | 325 (100) | 529 (88) | 211 (100) | 572 (66) | 819 (100) | 486 (75) | 413 (100) | 543 (88) | 274 (100) |
| CABG, No. (%) | | | | | | | | | | | | |
| Yes | 10 (1) | 0 (0) | 42 (5) | 0 (0) | 15 (2) | 0 (0) | 10 (1) | 0 (0) | 28 (4) | 0 (0) | 9 (1) | 0 (0) |
| No | 886 (99) | 531 (100) | 785 (95) | 325 (100) | 587 (98) | 211 (100) | 858 (99) | 819 (100) | 622 (96) | 413 (100) | 607 (99) | 274 (100) |

| | 2009 | | | | | | 2010 | | | | | | 2006-2010 | | | | | |
|---|---------------|--------------|-------------|--------------|-------------|-------------|---------------|--------------|-------------|--------------|-------------|--------------|--------------|---------------|--------------|---------------|--------------|--------------|
| | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA | STEMI | NSTEMI | UA |
| N | 1151 | 530 | 899 | 147 | 802 | 65 | 1054 | 748 | 738 | 270 | 451 | 140 | 4761 | 3369 | 3586 | 1372 | 2902 | 876 |
| Fibrinolytic therapy, No. (%) | | | | | | | | | | | | | | | | | | |
| Given | 800 (70) | 458 (86) | | | | | 689 (65) | 658 (88) | | | | | 3189 (67) | 2793 (83) | | | | |
| Not given – proceeded directly to primary angioplasty | 88 (8) | 2 (0) | | | | | 140 (13) | 0 (0) | | | | | 533 (11) | 16 (0) | | | | |
| Not given – Contraindicated | 60 (5) | 22 (4) | | | | | 46 (4) | 18 (2) | | | | | 198 (4) | 136 (4) | | | | |
| Not given – Missed thrombolysis | 168 (15) | 33 (6) | | | | | 145 (14) | 57 (8) | | | | | 661 (14) | 329 (10) | | | | |
| Not given – Others* | 35 (3) | 15 (3) | | | | | 34 (3) | 15 (2) | | | | | 180 (4) | 95 (3) | | | | |
| Percutaneous Coronary Intervention, No. (%) | | | | | | | | | | | | | | | | | | |
| Yes | 341 (30) | 0 (0) | 142 (16) | 0 (0) | 35 (4) | 0 (0) | 273 (26) | 0 (0) | 100 (14) | 0 (0) | 22 (5) | 0 (0) | 1470 (31) | 0 (0) | 657 (18) | 0 (0) | 224 (8) | 0 (0) |
| No | 810 (70) | 530 (100) | 757 (84) | 147 (100) | 65 (96) | 65 (100) | 781 (74) | 748 (100) | 638 (86) | 270 (100) | 429 (95) | 140 (100) | 3291 (69) | 3369 (100) | 2929 (82) | 1372 (100) | 2678 (92) | 876 (100) |
| CABG, No. (%) | | | | | | | | | | | | | | | | | | |
| Yes | 4 (0) | 0 (0) | 19 (2) | 0 (0) | 9 (1) | 0 (0) | 5 (0) | 0 (0) | 6 (1) | 0 (0) | 4 (1) | 0 (0) | 37 (1) | 0 (0) | 108 (3) | 2 (0) | 42 (1) | 0 (0) |
| No | 1147 (100) | 530 (100) | 880 (98) | 147 (100) | 793 (99) | 65 (100) | 1049 (100) | 748 (100) | 732 (99) | 270 (100) | 447 (99) | 140 (100) | 4724 (99) | 3369 (100) | 3478 (97) | 1370 (100) | 2860 (99) | 876 (100) |